New Report Available: Nanospectra Biosciences, Inc. - Product Pipeline Analysis, 2013 Update

Nanospectra Biosciences, Inc. (Nanospectra) is a life science company. The company develops and commercializes particle based therapies for the selective and precise thermal destruction of solid tumors. It offers AuroLase therapy that combines the unique physical and optical properties of AuroShell particles with an infrared laser source to thermally destroy cancer tissue without significant damage to surrounding healthy tissue. Nanospectra has license from Rice University to eleven issued US patents related to nanoshells and related commercial uses of these and other nanoparticles. It also offers research use only nanoparticles with specific optical characteristics. The company has an open investigational device exemption with the U.S. FDA to evaluate the safety and efficacy of AuroLase therapy for the treatment of refractory or recurrent head and neck cancers. Nanospectra is headquartered in Houston, Texas, the US.

Full Report Details at
- http://www.fastmr.com/prod/606063_nanospectra_biosciences_inc_product_pipeline.aspx?afid=301

This report is a source for data, analysis and actionable intelligence on the Nanospectra Biosciences, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

* Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
* Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
* Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
* Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
* Data on relevant clinical trials and product patent details, wherever applicable.
* Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Get this Report

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Predictive Biosciences, Inc. - Product Pipeline Analysis, 2013 Update
- TEI Biosciences, Inc. - Product Pipeline Analysis, 2013 Update
- Nanospectra Biosciences, Inc. - Product Pipeline Analysis
- GE Healthcare - Product Pipeline Analysis , 2013 Update
- Philips Healthcare - Product Pipeline Analysis, 2013 Update